Your browser doesn't support javascript.
loading
Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.
Carter, Gebra Cuyun; Kaltenboeck, Anna; Ivanova, Jasmina; Liepa, Astra M; San Roman, Alexandra; Koh, Maria; Rajan, Narayan; Cheng, Rebecca; Birnbaum, Howard G; Kim, Jong Seok; Bang, Yung-Jue.
Afiliação
  • Carter GC; Eli Lilly and Company, Indianapolis, IN, USA.
  • Kaltenboeck A; Analysis Group, New York, NY, USA.
  • Ivanova J; Analysis Group, New York, NY, USA.
  • Liepa AM; Eli Lilly and Company, Indianapolis, IN, USA.
  • San Roman A; Analysis Group, Boston, MA, USA.
  • Koh M; Analysis Group, New York, NY, USA.
  • Rajan N; Eli Lilly and Company, Sydney, Australia.
  • Cheng R; Eli Lilly and Company, Taipei, Taiwan.
  • Birnbaum HG; Analysis Group, Boston, MA, USA.
  • Kim JS; Eli Lilly and Company, Seoul, Korea.
  • Bang YJ; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Cancer Res Treat ; 49(3): 578-587, 2017 Jul.
Article em En | MEDLINE | ID: mdl-27618820
PURPOSE: The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. MATERIALS AND METHODS: Thirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan-Meier analysis was used to describe survival. RESULTS: Of 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumorswere located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity indexwas 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients. CONCLUSION: Most patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Padrões de Prática Médica Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Cancer Res Treat Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Padrões de Prática Médica Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Cancer Res Treat Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos